EPR Effect-Based Cancer Targeted Therapy: Commemorative Issue in Honor of Professor Hiroshi Maeda
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".
Deadline for manuscript submissions: closed (10 November 2022) | Viewed by 32846
Special Issue Editor
Interests: nanomedicine; tumor-targeting; EPR effect; carbon monoxide; inflammation; reactive oxygen species
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue of the Journal of Personalized Medicine entitled “EPR Effect-Based Cancer Targeted Therapy” is dedicated to Professor Hiroshi Maeda, the founder of the concept of the EPR effect, on the occasion of his unexpected passing.
Professor Maeda (1938–2021) was one of the most distinguished and influential scientists in the field of tumor targeting and nanomedicine, as well as in the field of reactive oxygen species (ROS) and viral infection. He graduated from Tohoku University, Japan (1962), followed by a master’s degree and PhD at the University of California, Davis (1962–1964), and Tohoku University (1964–1968), respectively. He carried out his postdoc study at the Dana-Farber Cancer Institute, Harvard University (1968–1971), which paved the way to his professorship at Tohoku University (1971–1981) and then Kumamoto University School of Medicine (1981–2004), where he developed the first polymer anticancer drug SMANCS and discovered the EPR effect with his colleague Dr. Matsumura. Now, the EPR effect has been becoming the basic concept of tumor targeting using nanomedicine and a standard for designing nanomedicine. In addition to the EPR effect, he was also the one who first reported that ROS is the major cause of pneumonia in influenza infection and that removal of ROS could effectively improve the progression of the disease, which I believe is a mechanism that could be applied to COVID-19-induced pneumonia. His scientific excellence and integrative personality were internationally recognized with numerous awards, including the Asagawa Award of the Japanese Society for Bacteriology (1995), Princess Takamatsu Cancer Research Fund Prizes (1997), Frey-Werle Award/Commemorative Gold Medal (1998), Life Time Achievement Award of the Royal Society of Pharmacy (2007), Nagai Award of the Japan Society of Drug Delivery System (2011), the Tomizo Yoshida Prize of the Japanese Cancer Association (2011), Thomson Reuters Citation Laureate (2016), Wayne State University Roland T. Lakey Award (2017), and the Order of the Sacred Treasure, Gold Rays with Neck Ribbon, Cabinet Office, Japan (2018).
Professor Maeda was a real scientist and excellent mentor. He developed various anticancer nanomedicines and carried out efforts for clinical application until his last day. Conquering Cancer and helping cancer patients were his lifelong dream, and we strongly believe this dream will become true, and EPR-based nanomedicine will be a solution to cancer.
We invite researchers to submit review articles and original articles for an in-depth understanding of the EPR effect and further exploitation of its effect on human cancer. New strategies for enhancement of the EPR effect using nanomedicine and imaging technology with the help of nanosize fluorogenic agents will be welcome.
Dr. Jun Fang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- EPR effect
- nanomedicine macromolecular drugs
- tumor delivery
- tumor targeting
- tumor imaging
- tumor selectivity
- tumor vasculature
- drug retention
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.